KARAHCO AS.


Startup for implementation, monitoring and evaluation of MedTech and healthcare projects in Norway and abroad

WHO WE ARE


KARAHCO AS is a Norwegian limited company (Aksjeselskap) founded in August 2021, as a reproduction of KARAHCO, a sole proprietorship (Enkeltpersonforetak) founded in 2015. The three main pipelines of services provided by KARAHCO AS are: Bacterial genome analysis, innovative molecular testing of pathogens, and external monitoring and evaluation of healthcare projects.

Innovative Thinking


By generating new ideas and solutions, we aim to challenge the current status quo of clinical microbiology testing technology


READ MORE

Business with Impact


We aim to make positive and measurable impacts on people, society, and the environment alongside with meeting our financial expectations


READ MORE

Tailored Diagnostics


Introducing new microbiology diagnostic routines to handle global public health concerns of antibiotic resistance and emerging pathogens 


READ MORE

NEWS AND EVENTS


In collaboration with partners from Norway, Sweden, Ethiopia, and Ghana, KARAHCO has recently applied to the "Metagenomic Next Generation Sequencing to Detect, Identify, and Characterize Pathogens" Global Grand Challenge announced by a joint initiative of the Bill and Melinda Gates Foundation and Chan Zuckerberg Initiative.

Picture1

Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) for COVID-19 Testing


READ MORE

Tele-Clinical Microbiology: An Innovative Approach to Providing Web-Enabled Diagnostic Laboratory Services


READ MORE

OUR PARTNERS

Under Progress

We are looking forward to working with you


If you have an enquiry about our products or services, please get in touch using our contact details below or by completing the online form